Incyte Corporation INCY is scheduled to report third-quarter 2026 earnings on Oct. 29, before the opening bell. The Zacks Consensus Estimate for the to-be-reported quarter’s revenues is pegged at $1.48 billion, while the same for the bottom line is pinned at a loss of $3.50 per share.
Let us look at how things are likely to have shaped up for INCY in the to-be-reported quarter.
Factors Likely to Influence INCY's Q3 Results
Incyte primarily derives product revenues from the sales of its lead drug, Jakafi (ruxolitinib), in the United States, as well as from the sales of other marketed drugs. Its momentum is likely to have continued on the back of strong Jakafi sales, a first-in-class, selective JAK1/JAK2 inhibitor, across all approved indications (polycythemia vera, myelofibrosis and refractory acute graft-versus-host disease [GvHD]).
The Zacks Consensus Estimate for Jakafi's third-quarter sales is pegged at $827 million.
Incyte also earns product royalty revenues from Novartis NVS for the commercialization of Jakafi in ex-U.S. markets.
While Incyte markets Jakafi in the United States, Novartis markets the same drug as Jakavi outside the United States. INCY is expected to have received higher royalties from NVS in the to-be-reported quarter due to potentially higher Jakavi sales.
Year to date, Incyte shares have gained 18.4% compared with the industry’s 6.7% growth.
Image Source: Zacks Investment Research
Incyte also receives royalties from the sales of Tabrecta (capmatinib), which is approved for treating adult patients with metastatic non-small cell lung cancer. Novartis has exclusive worldwide development and commercialization rights to Tabrecta.
In the to-be-reported quarter, Opzelura (ruxolitinib cream) sales are expected to have been driven by continued growth in patient starts and refills in the United States for its two approved indications: atopic dermatitis and vitiligo. The European Union (EU) approval of Opzelura for moderate atopic dermatitis is expected to support Incyte’s sales growth in the coming quarters by expanding the drug’s addressable market beyond its existing European vitiligo indication.
The CMS settlement is expected to support Opzelura’s net sales in the second half of 2026, with Incyte estimating a combined $40-$50 million benefit in the third and fourth quarters from improved gross-to-net performance.
The Zacks Consensus Estimate for Opzelura’s third-quarter sales is pegged at $230 million.
While Jakafi’s sales and royalties are the key catalysts for Incyte’s revenue growth, sales of other drugs like Minjuvi, Pemazyre and Iclusig, and Olumiant’s royalties from Eli Lilly LLY are also likely to have contributed to Incyte’s top line. INCY has a collaboration agreement with LLY for Olumiant. The drug is a once-daily oral JAK inhibitor discovered by Incyte and licensed to LLY. It is approved for several types of autoimmune diseases.
Incyte acquired exclusive global rights to Monjuvi/Minjuvi (tafasitamab), initially approved for the treatment of relapsed or refractory diffuse large B-cell lymphoma, from MorphoSys in 2024. Last year, the FDA approved Monjuvi for relapsed or refractory follicular lymphoma, expanding its label and boosting sales. Minjuvi also secured approvals for this indication in the EU and Japan in 2025.
The Zacks Consensus Estimate for Iclusig, Minjuvi/Monjuvi and Pemazyre’s third-quarter sales is pegged at $35.2 million, $55 million and $23.5 million, respectively. Incremental sales from Zynyz are also expected to have contributed to Incyte’s revenues in the to-be-reported quarter.
Incyte and partner Syndax launched Niktimvo (axatilimab-csfr) in the United States in early 2025 after FDA approval for chronic graft-versus-host disease (cGvHD) patients who have failed at least two prior systemic therapies. Niktimvo is Incyte's second approved treatment for cGvHD (third-line). The Zacks Consensus Estimate for Niktimvo’s third-quarter sales is pegged at $64 million.
Incyte granted Mirum Pharmaceuticals worldwide rights to Atebrioz (zilurgisertib) in April 2026. Following its FDA approval for fibrodysplasia ossificans progressiva, the drug is expected to launch this month. Incyte is eligible for milestone payments and royalties on global sales. Investors will look for updates on the launch and potential revenue contribution during the upcoming earnings call.
Higher research and development (R&D) expenses, as well as increased selling, general and administrative (SG&A) costs, are likely to have escalated operating expenses in the third quarter of 2026.
Incyte Corporation Price and Consensus
Incyte Corporation price-consensus-chart | Incyte Corporation Quote
INCY's Earnings Surprise History
Incyte has a mixed history of earnings surprises. The company beat earnings estimates in three of the trailing four quarters and missed in the remaining one, delivering an average surprise of 28.65%. In the last reported quarter, INCY posted an earnings surprise of 54.50%.
Earnings Whispers for INCY
Our proven model does not conclusively predict an earnings beat for INCY this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat. That is not the case here, as you will see below. You can uncover the best stocks to buy or sell before they are reported with our Earnings ESP Filter.
INCY’s Earnings ESP: Incyte’s Earnings ESP is -11.02% as the Most Accurate Estimate stands at a loss of $3.89, higher than the Zacks Consensus Estimate for a loss of $3.50. You can uncover the best stocks to buy or sell before they are reported with our Earnings ESP Filter.
INCY’s Zacks Rank: INCY has a Zacks Rank #4 (Sell) at present.
Stock to Consider
Here is a stock worth considering from the healthcare space, as our model shows that this has the right combination of elements to beat on earnings this reporting cycle.
Halozyme Therapeutics HALO has an Earnings ESP of +2.78% and currently flaunts a Zacks Rank #1 at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
HALO shares have gained 85.1% year to date. The company’s earnings beat estimates in three of the trailing four quarters and missed in the remaining one, delivering a negative average surprise of 19.12%. Halozyme is scheduled to report third-quarter results on Nov. 5.
Zacks' Research Chief Names "Stock Most Likely to Double"
Our team of experts has just released the 5 stocks with the greatest probability of gaining +100% or more in the coming months. Of those 5, Director of Research Sheraz Mian highlights the one stock set to climb highest.
This innovative software-as-a-service firm upped its user base +22% year over year. That rate is increasing and margins are expanding as AI efficiencies take effect. Of course, all our elite picks aren't winners, but this one could far surpass earlier Zacks' Stocks Set to Double like D-Wave Quantum, which shot up +680.1%.
Free: See Our Top Stock And 4 Runners UpWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Incyte Corporation (INCY): Free Stock Analysis Report
Novartis AG (NVS): Free Stock Analysis Report
Eli Lilly and Company (LLY): Free Stock Analysis Report
Halozyme Therapeutics, Inc. (HALO): Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).